Loading
Give patients a short course of one of several drug pairs in the gap before surgery and compare what happened inside the tumours. It is the fastest human test of whether a combination does anything.
Window-of-opportunity studies give a drug for 1 to 4 weeks between diagnosis and surgery and compare pre- and post-treatment tissue. Multi-arm windows randomising to several combinations with pharmacodynamic endpoints (proliferation, immune infiltration, target pathway suppression) can rank combinations by biological effect in under a year, before any efficacy trial.
Shares Pre-surgery platform trials that test combinations on pathological response in months, Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Lab models that fail to predict what happens in patients, Too many combinations to test, Colorectal cancer.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Too many combinations to test.
Shares Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy, Lab models that fail to predict what happens in patients, Too many combinations to test, Colorectal cancer.
Shares Single-cell & spatial profiling, Lab models that fail to predict what happens in patients, Too many combinations to test.